





**FIGURE 1**

**FIGURE 1 (CONTINUED)**


A.




B.




**FIGURE 2**


C.







D.

**FIGURE 2 (CONTINUED)**


**FIGURE 3****A.****B.****FIGURE 4**




**FIGURE 6**

A.**B.****FIGURE 7**


C.


**FIGURE 7 (continued)**

A.




B.


**FIGURE 8**



**FIGURE 9**

A.



B.

**FIGURE 10**

**FIGURE 11****FIGURE 12**






FIGURE 13

**FIGURE 14**







FIGURE 15


**FIGURE 16**

**FIGURE 17**

A.



B.

**FIGURE 18**





FIGURE 19






FIGURE 19 (CONTINUED)

D.

**FIGURE 19 (CONTINUED)****FIGURE 20**

Production in COS (surpernatant)				
ng/ml	VH WT	VHvAv3-23 (SEQ 37)	VHvAV1-46	VHvAv4-1
VL WT	1028,1	501,9	<12	<12
ng/ml	VL WT	VLvAv1-13 (SEQ 49)	VLvAv6-21	VLvAv3-11
VH WT	1028,1	2035,3	158,6	75,3
VHvAv3-23 (SEQ 37)	501,9	861,1	-	-

Production in CHO (surpernatant)				
ng/ml	VH WT	VHvAv3-23 (SEQ 37)	VHvAV1-46	VHvAv4-1
VL WT	509,3	249,7	<12	<12
ng/ml	VL WT	VLvAv1-13 (SEQ 49)	VLvAv6-21	VLvAv3-11
VH WT	509,3	831,3	78,4	40,4
VHvAv3-23 (SEQ 37)	249,7	443,7	-	-

FIGURE 21

Production in CHO cells and purification on Protein A		
	Concentration (mg/ml)	Yield (mg/L)
VH WT + VL WT	2,8	33,6
VH WT + VLvAv1-13 (SEQ 49)	0,96	4
VHvAv3-23 (SEQ 37) + VLvAv1-13 (SEQ 49)	2,3	21,08

FIGURE 22







FIGURE 23



	ED50 (ng/ml)
2G1wt	269,2
HALA	557,3
HCLC	167,4
HCLD	332,9
HDLC	196,6
HDLD	195,1


FIGURE 24**FIGURE 25**



**FIGURE 26**


C.

ROS production

**FIGURE 26**

**FIGURE 27**

**FIGURE 28****FIGURE 29**

**FIGURE 30**

A.




FIGURE 31

B.







FIGURE 31 (continued)

**FIGURE 32**

A.




B.

	ED50 (ng/ml)
2G1wt #170919	222,0
HALA#170919	253,4
HALA	194,5
HDLD	192,6
HD-LDT52S	237,4
HEF-LDT52S	125,7
HEF-LEF	182,8

FIGURE 33

A.

**FIGURE 34**

B.

		-80°C		d7 at 37°C	
	loading	% aggregates	% monomers	% aggregates	% monomers
HDLD	100µl à 0,18mg/ml	7,9	92,1	5	95
HEF-LDT52S	100µl à 0,15mg/ml	2,8	97,2	4,3	95,7

FIGURE 34 (continued)




FIGURE 35




FIGURE 36